Tejal Somvanshi
Popular diabetes drug Ozempic shows surprising 52% drop in kidney disease markers among non-diabetic patients - how will this reshape CKD treatment?
Photo Source: Google
Research team's 24-week trial demonstrates Ozempic slashed urinary protein levels while reducing inflammation by 30% in CKD patients.
Participants experienced a remarkable 33% improvement in heart failure indicators alongside a 10% average weight reduction.
International study shows blood pressure improvements matching traditional medications' effectiveness - without the usual side effects.
Even after treatment ended, kidney health markers remained significantly improved, suggesting lasting benefits for patients.
Dr. Heerspink's team observed both direct anti-inflammatory effects and indirect benefits through weight loss in kidney tissues.
Can Ozempic potentially reduce future dialysis needs and kidney transplants? Scientists are eager to investigate.
Study focused exclusively on non-diabetic patients with specific kidney function levels and BMI requirements.
Despite supply shortages limiting broader research, initial results position Ozempic as a promising option for CKD patients managing obesity.
Lead-Contaminated Turmeric From South Asia: 1000 Micrograms Per GramβA Silent Global Health Crisis